Genocea Biosciences, which is developing novel vaccines for infectious diseases through T cell immune responses, filed on Monday with the SEC to raise up to $75 million in an initial public offering. Venture backers include Polaris Venture Partners (16% pre-IPO stake), Lux Ventures (15%), S.R. One (13%), Johnson & Johnson (12%), CVF, an affiliate of Henry Crown and Company (9%), Skyline Venture Partners (9%), Cycad Group (7%), Auriga Ventures (7%) and Bill & Melinda Gates Foundation (6%).
The Cambridge, MA-based company, which was founded in 2006, plans to list on the NASDAQ under the symbol GNCA. Genocea Biosciences initially filed confidentially on October 22, 2013. Citi and Cowen & Company are the lead bookrunners on the deal. No pricing terms were disclosed.
